These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 19295545)

  • 1. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.
    Mustjoki S; Ekblom M; Arstila TP; Dybedal I; Epling-Burnette PK; Guilhot F; Hjorth-Hansen H; Höglund M; Kovanen P; Laurinolli T; Liesveld J; Paquette R; Pinilla-Ibarz J; Rauhala A; Shah N; Simonsson B; Sinisalo M; Steegmann JL; Stenke L; Porkka K
    Leukemia; 2009 Aug; 23(8):1398-405. PubMed ID: 19295545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Large granular lymphocytosis during dasatinib therapy.
    Qiu ZY; Xu W; Li JY
    Cancer Biol Ther; 2014 Mar; 15(3):247-55. PubMed ID: 24352048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
    Paydas S
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct effect of dasatinib on proliferation and cytotoxicity of natural killer cells in in vitro study.
    Uchiyama T; Sato N; Narita M; Yamahira A; Iwabuchi M; Furukawa T; Sone H; Takahashi M
    Hematol Oncol; 2013 Sep; 31(3):156-63. PubMed ID: 23108877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
    Hoshino T; Tahara K; Miyawaki K; Hatsumi N; Takada S; Miyawaki S; Sakura T
    Rinsho Ketsueki; 2010 Mar; 51(3):181-8. PubMed ID: 20379112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia.
    Kim DH; Kamel-Reid S; Chang H; Sutherland R; Jung CW; Kim HJ; Lee JJ; Lipton JH
    Haematologica; 2009 Jan; 94(1):135-9. PubMed ID: 19066329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
    Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
    Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.
    Tanaka H; Nakashima S; Usuda M
    Int J Hematol; 2012 Sep; 96(3):308-19. PubMed ID: 22767140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
    Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
    Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
    Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
    Am J Hematol; 2015 Sep; 90(9):819-24. PubMed ID: 26103598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion.
    Nagata Y; Ohashi K; Fukuda S; Kamata N; Akiyama H; Sakamaki H
    Int J Hematol; 2010 Jun; 91(5):799-807. PubMed ID: 20405252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
    Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
    Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacological properties and clinical efficacy of dasatinib hydrate (Sprycel), an anticancer drug for chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia].
    Fujii Y; Amano M; Seriu T
    Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):159-67. PubMed ID: 19749489
    [No Abstract]   [Full Text] [Related]  

  • 15. Dasatinib.
    Lindauer M; Hochhaus A
    Recent Results Cancer Res; 2010; 184():83-102. PubMed ID: 20072833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib: BMS 354825.
    Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.
    Lilly MB; Ottmann OG; Shah NP; Larson RA; Reiffers JJ; Ehninger G; Müller MC; Charbonnier A; Bullorsky E; Dombret H; Brigid Bradley-Garelik M; Zhu C; Martinelli G
    Am J Hematol; 2010 Mar; 85(3):164-70. PubMed ID: 20131302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients.
    Watanabe N; Takaku T; Takeda K; Shirane S; Toyota T; Koike M; Noguchi M; Hirano T; Fujiwara H; Komatsu N
    Int J Hematol; 2018 Dec; 108(6):588-597. PubMed ID: 30151740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
    Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.